Abstract | BACKGROUND: METHODS AND RESULTS: Fifty-four patients (age 24-82 years; 65% women) undergoing ASA were randomized into 2 groups according to the dose of injected ethanol: Group A 1-2 ml, Group B >2 ml. Clinical and echocardiographic data were obtained at baseline and during follow-up. The volume of ethanol injected was 1.50+/-0.4 and 2.60+/-0.6 ml (p<0.001) with a subsequent peak of creatine kinase-MB of 2.25+/-1.00 and 2.62+/-1.57 microkat/L (p=0.02) in Groups A and B, respectively. The median follow-up was 39 (range 6-72) months after ASA, during which 1 patient died and 1 repeat procedure was necessary in both groups of patients. Both groups had a significant and similar improvement in outflow pressure gradient, dyspnea (New York Heart Association functional class) and angina pectoris (Canadian Cardiovascular Society class) (p<0.001). There was a significant decrease in the left ventricular ejection fraction (LVEF) in Group B (81+/-7 vs 75+/-7%; p=0.002), but not in Group A (80+/-7 vs 79+/-7%; p=0.67). Thinning of the basal septum was more pronounced in Group B than in Group A (9.3+/-5.7 vs 6.6+/-3.4 mm; p=0.04). CONCLUSIONS: A lower dose of ethanol injected into the target septal branch reduces both the size of necrosis and subsequent thinning of the basal septum, and preserves LVEF during long-term follow-up. Moreover, the low dose (1-2 ml) is as safe and as hemodynamically efficacious as higher doses.
|
Authors | Josef Veselka, Radka Duchonová, Jana Páleníckova, David Zemánek, Marie Tiserová, Katerina Linhartová, Pavel Cervinka |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 70
Issue 12
Pg. 1550-2
(Dec 2006)
ISSN: 1346-9843 [Print] Japan |
PMID | 17127797
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cardiovascular Agents
- Ethanol
|
Topics |
- Adult
- Aged
- Cardiac Catheterization
- Cardiomyopathy, Hypertrophic
(therapy)
- Cardiovascular Agents
(administration & dosage)
- Ethanol
(administration & dosage)
- Female
- Humans
- Injections, Intralesional
- Male
- Middle Aged
- Prospective Studies
- Treatment Outcome
|